Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Short Sellers Are Targeting Advanced Micro Devices, Inc. (AMD) Stock

We recently published a list of Jefferies’ Top Crowded Semiconductor Short Positions: Top 10 Stocks. In this article, we are going to take a look at where Advanced Micro Devices, Inc. (NASDAQ:AMD) stands against other Jefferies’ top crowded semiconductor short positions’ stocks.

With the third quarter earnings season with us, the semiconductor industry continues to be filled with surprises. 2023 and the better part of 2024 have seen investors remain bullish about chips due to the increased market size resulting from artificial intelligence. Yet–at the same time–the pipers of Wall Street have also been wary of over-investing in artificial intelligence and the state of the broader chip manufacturing industry apart from the fortunes of the AI industry.

For the latter front, October has been quite eventful. It once again reminded us that even the firms closest to a monopoly these days aren’t immune from either macroeconomic headwinds or from worried investors. It saw the shares of the most important company in the semiconductor industry tank by a stunning 21.64% in just two days after a rather interesting set of events.

This stock ranked 8th on our recent list of AI stocks that were trending in the news and this was unsurprising. It was due to report its earnings on October 16th, but the report ended up leaking a day earlier. Earnings leaks are a serious matter, and even more so for this firm since its business provides investors with early insight into the affairs of the semiconductor industry ahead of an earnings cycle for other firms.

The leaked earnings saw the firm guide its 2025 net sales at a midpoint of €32.5 billion as it warned that the weakness in the semiconductor industry “is expected to continue in 2025, which is leading to customer cautiousness.” Since its machines are booked months in advance, the firm has a greater insight into its future cash flows than others, and investors were further spooked by its bookings. The bookings sat at €2.6 billion as of the third quarter, for a wide miss over midpoint analyst estimates of €5 billion.

Consequently, investors weren’t impressed. The day that the earnings report leaked, the shares dropped by 16% for their biggest one-day drop in more than two decades. They continued their downward spiral the following day to close 6.42% lower and extend the two-day cumulative drop to 21.64%. While these drops might seem to be a bit too much since after all, you don’t see multi-decade records get broken every day, they stem from the uncertainty that investors have to contend with when analyzing complex industries such as semiconductor fabrication.

Broadly speaking, the semiconductor industry is divided into three tiers. Starting from the top, firms like GPU and CPU designers are responsible for selling products to consumers and businesses. The second tier is made of manufacturers which produce the chips and the third is made of firms that provide the manufacturing equipment. Consequently, the fact that the chip manufacturing equipment provider’s downbeat revenue guidance wiped off billions of dollars of capital from the semiconductor industry was unsurprising.

As per Bloomberg, following the bookings miss and lower guidance, US-listed chip stocks, and Asian stocks bled a collective $420 billion in value. Michael Roeg, an analyst at investment bank Petercam Degroof provided more color into the drop. After the release, he shared that sales trends at the world’s largest contract chip manufacturer “are a misleading indicator for the overall health of the semiconductor industry.” This is because the firm “has been spending rather low capex numbers so far this year, and they may do so again next year because their overall (plant) utilization is not as good as their sales numbers suggest.”

Utilization refers to the percentage of time that expensive chip machines are running and producing chips and fabs prefer to have high rates since it decreases the time it takes for them to recuperate their investment. Low capital expenditure affects utilization since if utilization is low then chip manufacturers do not feel the need to spend heavily for new machines. In sum, these trends mean that semiconductor spending at the bottom tier of the industry remains muted unless demand picks up and utilization grows.

Shifting gears, the top tier of the industry is divided into several categories. One category includes firms like Wall Street’s favorite AI stock, the GPU designer whose shares are up 198% year-to-date. Due to the market’s rush into AI, while investors have been kind to this firm, they have been far more prudent for others. One such firm is responsible for manufacturing silicon carbide chips that are used for power management by electric vehicles. Since the demand for EV vehicles has slowed, leading to the shares of Elon Musk’s car company losing 12.3% year to date, the shares of this firm haven’t done well either. They are down 18.3% year to date, and if you’re interested in knowing more about this stock, we’ve included it in today’s list.

This overall bifurcation in the semiconductor industry hasn’t skipped the attention of institutional investors. According to Jefferies’ October Trading Positioning Survey, the percentage of investors overweight on semiconductor stocks was 42%, a strong 18-point drop over July’s figures. The funds that were underweight on these stocks grew by five points from July to sit at 16%, so let’s take a look at the stocks that they have shorted.

Our Methodology

To make our list of Jefferies’ top overcrowded semiconductor short positions, we ranked the top ten crowded short positions from the latest Trading Positioning Survey by their shares short as a percentage of outstanding shares.

For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).

A close up of a complex looking PCB board with several intergrated semiconductor parts.

Advanced Micro Devices, Inc. (NASDAQ:AMD)

Number of Hedge Fund Holders In Q2 2024: 108

Shares Short % Of Outstanding: 2.76%

Advanced Micro Devices, Inc. (NASDAQ:AMD) is a semiconductor design company. The firm designs and sells CPUs and GPUs for a variety of use cases. These include personal computers, gaming consoles, data centers, and AI use cases. This makes Advanced Micro Devices, Inc. (NASDAQ:AMD) the only firm in the world that simultaneously competes with both NVIDIA and Intel. The firm has benefited from Intel’s struggles and leverages product design along with TSMC’s manufacturing technologies to gain market share over the larger firm. Additionally, in a price-constrained environment, Advanced Micro Devices, Inc. (NASDAQ:AMD) benefits because of its affordability, and its smaller size also easily captures market share. The firm has been making aggressive investments in AI recently through multiple acquisitions that are aimed at bolstering its position in the data center industry. However, these acquisitions come at a cost and Advanced Micro Devices, Inc. (NASDAQ:AMD) has been debt-stressed until very recently so future leverage might create a headwind.

Baron Funds mentioned Advanced Micro Devices, Inc. (NASDAQ:AMD) in its Q2 2024 investor letter. Here is what the fund said:

Advanced Micro Devices, Inc. (AMD) is a global fabless semiconductor company focusing on high performance computing technology, software, and products including CPUs, 9 GPUs, FPGAs, 10 and others. Shares of AMD remain volatile, and after a strong run earlier in the year, the stock fell during the quarter as investors continue to wrestle with AMD’s competitive positioning in the AI compute market relative to NVIDIA, who continues to strengthen its full-system solution offerings at a rapid pace. AMD also updated its MI300 GPU chip revenue expectations for the full year to “greater than $4 billion” vs. prior $3.5 billion, which disappointed the market a bit relative to high expectations. Over the long-term, we believe AMD, with its unique chiplet-based architecture and open-source software ecosystem, will play a meaningful role in the rapidly growing AI compute market, where customers don’t want to be locked into a single vendor and AMD offers a compelling total-cost-of-ownership proposition, especially in inferencing workloads. Simultaneously, we believe AMD will continue to take share from Intel within traditional data center CPUs, which, while now a slower growth market, is likely to see a near-term refresh as data centers look for ways to improve energy efficiency and optimize existing footprints.”

Overall, AMD ranks 5th on our list of Jefferies’ top crowded semiconductor short positions’ stocks. While we acknowledge the potential of AMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than AMD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article is originally published at Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

Penicillin Changed the World. This Drug Could Too

This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses Including a single drug to treat COVID, RSV, FLU and even Monkey-pox!

This is a clinical-stage, global leader in broad-spectrum antiviral nanomedicines who is developing therapeutic drugs that work safely and effectively, even against emerging variants!

A novel broad-spectrum antiviral

NV-387,  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, the company has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Click to continue reading…